Jingyi Xiang

1.5k total citations · 1 hit paper
16 papers, 1.0k citations indexed

About

Jingyi Xiang is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jingyi Xiang has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jingyi Xiang's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Erythrocyte Function and Pathophysiology (2 papers). Jingyi Xiang is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Erythrocyte Function and Pathophysiology (2 papers). Jingyi Xiang collaborates with scholars based in United States, China and Spain. Jingyi Xiang's co-authors include Liu C, Su Yan, Pei Wang, Mei Song, Renier J. Brentjens, Sarwish Rafiq, Oladapo Yeku, Xiaojing Ma, Dylan J. Drakes and Dayenne G. van Leeuwen and has published in prestigious journals such as Nature Communications, Blood and Nature Biotechnology.

In The Last Decade

Jingyi Xiang

14 papers receiving 988 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

2018 628 citations Sarwish Rafiq, Oladapo Yeku et al. Nature Biotechnology profile →

Peers

Jingyi Xiang

ONCOL

IMMUN

MB

BE

GENET

Bruno L. Cadilha Germany

Christof C. Smith United States

Anusha Rajan United States

Andrew D. Fesnak United States

Elizabeth L. Siegler United States

Nicole Berndt Germany

Noor Momin United States

Thomas J. Fountaine United States

Konstantin Dobrenkov United States

Bruno L. Cadilha Germany

Jingyi Xiang

945 ×1.2

ONCOL

560 ×1.2

IMMUN

393 ×1.1

MB

277 ×1.1

BE

183 ×1.0

GENET

Citations per year, relative to Jingyi Xiang Jingyi Xiang (= 1×) peers Bruno L. Cadilha

Countries citing papers authored by Jingyi Xiang

Since Specialization

Citations

This map shows the geographic impact of Jingyi Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingyi Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingyi Xiang more than expected).

Fields of papers citing papers by Jingyi Xiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingyi Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingyi Xiang. The network helps show where Jingyi Xiang may publish in the future.

Co-authorship network of co-authors of Jingyi Xiang

This figure shows the co-authorship network connecting the top 25 collaborators of Jingyi Xiang. A scholar is included among the top collaborators of Jingyi Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingyi Xiang. Jingyi Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Xi, Lei, Yangfan Lv, Lin Zhang, et al.. (2025). USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation. Nature Communications. 16(1). 1313–1313. 3 indexed citations

2.

Lin, Yuxiang, et al.. (2024). Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis. Medicine. 103(20). e38018–e38018. 4 indexed citations

3.

Xiang, Jingyi, et al.. (2024). DG-RainDiff: Depth-Guided Dynamic Message Passing Diffusion Model for Mixture of Rain Removal. 6280–6284.

4.

Xiang, Jingyi, et al.. (2021). A model‐driven robust deep learning wireless transceiver. IET Communications. 15(17). 2252–2258. 1 indexed citations

5.

Li, Tianhong, et al.. (2019). Abstract 4019: High TERT expression in NSCLC is associated with poor prognosis. 4019–4019.

6.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2018). Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology. 36(9). 847–856. 628 indexed citations breakdown →

7.

Ahmed, Mahiuddin, Andrés López‐Albaitero, Dmitry Pankov, et al.. (2018). TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 3(4). 34 indexed citations

8.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2017). Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade. Blood. 130(Suppl_1). 842–842. 6 indexed citations

9.

Rao, Thapi D., Alberto Fernández‐Tejada, Abram Axelrod, et al.. (2017). Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. ACS Chemical Biology. 12(8). 2085–2096. 34 indexed citations

10.

Liu, Hong, Yiyang Xu, Jingyi Xiang, et al.. (2016). Abstract 2299: ET1402L1-CART, a T cell therapy targeting the intracellular tumor antigen AFP, demonstrates potent antitumor activity in hepatocellular carcinoma models. Cancer Research. 76(14_Supplement). 2299–2299. 1 indexed citations

11.

Dao, Tao, Dmitry Pankov, Andrew Scott, et al.. (2015). Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology. 33(10). 1079–1086. 126 indexed citations

12.

Ataie, Niloufar, Jingyi Xiang, Elliott J. Brea, et al.. (2015). Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. Journal of Molecular Biology. 428(1). 194–205. 47 indexed citations

13.

Veomett, Nicholas, Tao Dao, Hong Liu, et al.. (2014). Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein. Clinical Cancer Research. 20(15). 4036–4046. 41 indexed citations

14.

Xiang, Jingyi, Juyeon Jung, & Nicole S. Sampson. (2004). Entropy Effects on Protein Hinges: The Reaction Catalyzed by Triosephosphate Isomerase. Biochemistry. 43(36). 11436–11445. 39 indexed citations

15.

Xiang, Jingyi, Jeonghoon Sun, & Nicole S. Sampson. (2001). The importance of hinge sequence for loop function and catalytic activity in the reaction catalyzed by triosephosphate isomerase 1 1Edited by P. E. Wright. Journal of Molecular Biology. 307(4). 1103–1112. 32 indexed citations

16.

Wright, Philip, et al.. (1999). Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.. PubMed. 5(6). 371–9. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact